The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hematological Cancers-Global Market Insights and Sales Trends 2024
Synopsis
hematologic cancer. Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma. Also called blood cancer.
The global Hematological Cancers market size is expected to reach US$ 99850 million by 2029, growing at a CAGR of 7.7% from 2023 to 2029. The market is mainly driven by the significant applications of Hematological Cancers in various end use industries. The expanding demands from the Epidemiology, Pathophysiology of Leukemic Stem Cells, Kidney Diseases and Genetic Diseases, are propelling Hematological Cancers market. Pharmacological Therapies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Stem Cell Transplantation segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hematological Cancers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hematological Cancers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hematological Cancers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hematological Cancers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hematological Cancers covered in this report include Karyopharm Therapeutics, Johnson & Johnson, Roche Diagnostics A/S, AbbVie, Novartis, Kite Pharma, Celgene Corporation, Abbott Laboratories and Beckman Coulter, etc.
The global Hematological Cancers market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
HemoCue AB
C. R. Bard
Siemens AG
Sysmex
Mindray Medical International Limited
Bio-Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba
DiagnoCure Inc.
Astellas Pharma US
Global Hematological Cancers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hematological Cancers market, Segment by Type:
Pharmacological Therapies
Stem Cell Transplantation
Surgery and Radiation Therapy
Anemia Treatment
Thrombosis Treatment
Neutopenia Treatment
Symptomatic treatment
Global Hematological Cancers market, by Application
Epidemiology
Pathophysiology of Leukemic Stem Cells
Kidney Diseases
Genetic Diseases
Other Diseases
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hematological Cancers companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
hematologic cancer. Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma. Also called blood cancer.
The global Hematological Cancers market size is expected to reach US$ 99850 million by 2029, growing at a CAGR of 7.7% from 2023 to 2029. The market is mainly driven by the significant applications of Hematological Cancers in various end use industries. The expanding demands from the Epidemiology, Pathophysiology of Leukemic Stem Cells, Kidney Diseases and Genetic Diseases, are propelling Hematological Cancers market. Pharmacological Therapies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Stem Cell Transplantation segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hematological Cancers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hematological Cancers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hematological Cancers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hematological Cancers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hematological Cancers covered in this report include Karyopharm Therapeutics, Johnson & Johnson, Roche Diagnostics A/S, AbbVie, Novartis, Kite Pharma, Celgene Corporation, Abbott Laboratories and Beckman Coulter, etc.
The global Hematological Cancers market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
HemoCue AB
C. R. Bard
Siemens AG
Sysmex
Mindray Medical International Limited
Bio-Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba
DiagnoCure Inc.
Astellas Pharma US
Global Hematological Cancers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hematological Cancers market, Segment by Type:
Pharmacological Therapies
Stem Cell Transplantation
Surgery and Radiation Therapy
Anemia Treatment
Thrombosis Treatment
Neutopenia Treatment
Symptomatic treatment
Global Hematological Cancers market, by Application
Epidemiology
Pathophysiology of Leukemic Stem Cells
Kidney Diseases
Genetic Diseases
Other Diseases
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hematological Cancers companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hematological Cancers
1.1 Hematological Cancers Market Overview
1.1.1 Hematological Cancers Product Scope
1.1.2 Hematological Cancers Market Status and Outlook
1.2 Global Hematological Cancers Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hematological Cancers Market Size by Region (2018-2029)
1.4 Global Hematological Cancers Historic Market Size by Region (2018-2023)
1.5 Global Hematological Cancers Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hematological Cancers Market Size (2018-2029)
1.6.1 North America Hematological Cancers Market Size (2018-2029)
1.6.2 Europe Hematological Cancers Market Size (2018-2029)
1.6.3 Asia-Pacific Hematological Cancers Market Size (2018-2029)
1.6.4 Latin America Hematological Cancers Market Size (2018-2029)
1.6.5 Middle East & Africa Hematological Cancers Market Size (2018-2029)
2 Hematological Cancers Market by Type
2.1 Introduction
2.1.1 Pharmacological Therapies
2.1.2 Stem Cell Transplantation
2.1.3 Surgery and Radiation Therapy
2.1.4 Anemia Treatment
2.1.5 Thrombosis Treatment
2.1.6 Neutopenia Treatment
2.1.7 Symptomatic treatment
2.2 Global Hematological Cancers Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hematological Cancers Historic Market Size by Type (2018-2023)
2.2.2 Global Hematological Cancers Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hematological Cancers Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hematological Cancers Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hematological Cancers Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hematological Cancers Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hematological Cancers Revenue Breakdown by Type (2018-2029)
3 Hematological Cancers Market Overview by Application
3.1 Introduction
3.1.1 Epidemiology
3.1.2 Pathophysiology of Leukemic Stem Cells
3.1.3 Kidney Diseases
3.1.4 Genetic Diseases
3.1.5 Other Diseases
3.2 Global Hematological Cancers Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hematological Cancers Historic Market Size by Application (2018-2023)
3.2.2 Global Hematological Cancers Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hematological Cancers Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hematological Cancers Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hematological Cancers Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hematological Cancers Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hematological Cancers Revenue Breakdown by Application (2018-2029)
4 Hematological Cancers Competition Analysis by Players
4.1 Global Hematological Cancers Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hematological Cancers as of 2022)
4.3 Date of Key Players Enter into Hematological Cancers Market
4.4 Global Top Players Hematological Cancers Headquarters and Area Served
4.5 Key Players Hematological Cancers Product Solution and Service
4.6 Competitive Status
4.6.1 Hematological Cancers Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Karyopharm Therapeutics
5.1.1 Karyopharm Therapeutics Profile
5.1.2 Karyopharm Therapeutics Main Business
5.1.3 Karyopharm Therapeutics Hematological Cancers Products, Services and Solutions
5.1.4 Karyopharm Therapeutics Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.1.5 Karyopharm Therapeutics Recent Developments
5.2 Johnson & Johnson
5.2.1 Johnson & Johnson Profile
5.2.2 Johnson & Johnson Main Business
5.2.3 Johnson & Johnson Hematological Cancers Products, Services and Solutions
5.2.4 Johnson & Johnson Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.2.5 Johnson & Johnson Recent Developments
5.3 Roche Diagnostics A/S
5.3.1 Roche Diagnostics A/S Profile
5.3.2 Roche Diagnostics A/S Main Business
5.3.3 Roche Diagnostics A/S Hematological Cancers Products, Services and Solutions
5.3.4 Roche Diagnostics A/S Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.3.5 AbbVie Recent Developments
5.4 AbbVie
5.4.1 AbbVie Profile
5.4.2 AbbVie Main Business
5.4.3 AbbVie Hematological Cancers Products, Services and Solutions
5.4.4 AbbVie Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.4.5 AbbVie Recent Developments
5.5 Novartis
5.5.1 Novartis Profile
5.5.2 Novartis Main Business
5.5.3 Novartis Hematological Cancers Products, Services and Solutions
5.5.4 Novartis Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.5.5 Novartis Recent Developments
5.6 Kite Pharma
5.6.1 Kite Pharma Profile
5.6.2 Kite Pharma Main Business
5.6.3 Kite Pharma Hematological Cancers Products, Services and Solutions
5.6.4 Kite Pharma Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.6.5 Kite Pharma Recent Developments
5.7 Celgene Corporation
5.7.1 Celgene Corporation Profile
5.7.2 Celgene Corporation Main Business
5.7.3 Celgene Corporation Hematological Cancers Products, Services and Solutions
5.7.4 Celgene Corporation Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.7.5 Celgene Corporation Recent Developments
5.8 Abbott Laboratories
5.8.1 Abbott Laboratories Profile
5.8.2 Abbott Laboratories Main Business
5.8.3 Abbott Laboratories Hematological Cancers Products, Services and Solutions
5.8.4 Abbott Laboratories Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.8.5 Abbott Laboratories Recent Developments
5.9 Beckman Coulter
5.9.1 Beckman Coulter Profile
5.9.2 Beckman Coulter Main Business
5.9.3 Beckman Coulter Hematological Cancers Products, Services and Solutions
5.9.4 Beckman Coulter Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.9.5 Beckman Coulter Recent Developments
5.10 HemoCue AB
5.10.1 HemoCue AB Profile
5.10.2 HemoCue AB Main Business
5.10.3 HemoCue AB Hematological Cancers Products, Services and Solutions
5.10.4 HemoCue AB Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.10.5 HemoCue AB Recent Developments
5.11 C. R. Bard
5.11.1 C. R. Bard Profile
5.11.2 C. R. Bard Main Business
5.11.3 C. R. Bard Hematological Cancers Products, Services and Solutions
5.11.4 C. R. Bard Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.11.5 C. R. Bard Recent Developments
5.12 Siemens AG
5.12.1 Siemens AG Profile
5.12.2 Siemens AG Main Business
5.12.3 Siemens AG Hematological Cancers Products, Services and Solutions
5.12.4 Siemens AG Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.12.5 Siemens AG Recent Developments
5.13 Sysmex
5.13.1 Sysmex Profile
5.13.2 Sysmex Main Business
5.13.3 Sysmex Hematological Cancers Products, Services and Solutions
5.13.4 Sysmex Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.13.5 Sysmex Recent Developments
5.14 Mindray Medical International Limited
5.14.1 Mindray Medical International Limited Profile
5.14.2 Mindray Medical International Limited Main Business
5.14.3 Mindray Medical International Limited Hematological Cancers Products, Services and Solutions
5.14.4 Mindray Medical International Limited Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.14.5 Mindray Medical International Limited Recent Developments
5.15 Bio-Rad Laboratories
5.15.1 Bio-Rad Laboratories Profile
5.15.2 Bio-Rad Laboratories Main Business
5.15.3 Bio-Rad Laboratories Hematological Cancers Products, Services and Solutions
5.15.4 Bio-Rad Laboratories Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.15.5 Bio-Rad Laboratories Recent Developments
5.16 The Medicine Company
5.16.1 The Medicine Company Profile
5.16.2 The Medicine Company Main Business
5.16.3 The Medicine Company Hematological Cancers Products, Services and Solutions
5.16.4 The Medicine Company Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.16.5 The Medicine Company Recent Developments
5.17 Pharmacyclics
5.17.1 Pharmacyclics Profile
5.17.2 Pharmacyclics Main Business
5.17.3 Pharmacyclics Hematological Cancers Products, Services and Solutions
5.17.4 Pharmacyclics Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.17.5 Pharmacyclics Recent Developments
5.18 Horiba
5.18.1 Horiba Profile
5.18.2 Horiba Main Business
5.18.3 Horiba Hematological Cancers Products, Services and Solutions
5.18.4 Horiba Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.18.5 Horiba Recent Developments
5.19 DiagnoCure Inc.
5.19.1 DiagnoCure Inc. Profile
5.19.2 DiagnoCure Inc. Main Business
5.19.3 DiagnoCure Inc. Hematological Cancers Products, Services and Solutions
5.19.4 DiagnoCure Inc. Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.19.5 DiagnoCure Inc. Recent Developments
5.20 Astellas Pharma US
5.20.1 Astellas Pharma US Profile
5.20.2 Astellas Pharma US Main Business
5.20.3 Astellas Pharma US Hematological Cancers Products, Services and Solutions
5.20.4 Astellas Pharma US Hematological Cancers Revenue (US$ Million) & (2018-2023)
5.20.5 Astellas Pharma US Recent Developments
6 North America
6.1 North America Hematological Cancers Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hematological Cancers Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hematological Cancers Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hematological Cancers Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hematological Cancers Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hematological Cancers Market Dynamics
11.1 Hematological Cancers Industry Trends
11.2 Hematological Cancers Market Drivers
11.3 Hematological Cancers Market Challenges
11.4 Hematological Cancers Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
